- Home
- RIGL vs ABSI Comparison
RIGL vs ABSI Comparison
Compare RIGL & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- ABSI
- Stock Information
- Founded
- RIGL 1996
- ABSI 2011
- Country
- RIGL United States
- ABSI United States
- Employees
- RIGL N/A
- ABSI N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- RIGL Health Care
- ABSI Health Care
- Exchange
- RIGL Nasdaq
- ABSI Nasdaq
- Market Cap
- RIGL 335.5M
- ABSI 338.0M
- IPO Year
- RIGL 2000
- ABSI 2021
- Fundamental
- Price
- RIGL $41.50
- ABSI $2.63
- Analyst Decision
- RIGL Buy
- ABSI Strong Buy
- Analyst Count
- RIGL 5
- ABSI 5
- Target Price
- RIGL $38.20
- ABSI $7.98
- AVG Volume (30 Days)
- RIGL 845.0K
- ABSI 5.6M
- Earning Date
- RIGL 08-05-2025
- ABSI 08-12-2025
- Dividend Yield
- RIGL N/A
- ABSI N/A
- EPS Growth
- RIGL N/A
- ABSI N/A
- EPS
- RIGL 5.43
- ABSI N/A
- Revenue
- RIGL $267,921,000.00
- ABSI $4,138,000.00
- Revenue This Year
- RIGL $14.41
- ABSI $74.53
- Revenue Next Year
- RIGL $15.97
- ABSI $296.01
- P/E Ratio
- RIGL $7.64
- ABSI N/A
- Revenue Growth
- RIGL 105.62
- ABSI 27.32
- 52 Week Low
- RIGL $12.00
- ABSI $2.01
- 52 Week High
- RIGL $43.72
- ABSI $6.33
- Technical
- Relative Strength Index (RSI)
- RIGL 86.20
- ABSI 40.89
- Support Level
- RIGL $38.43
- ABSI $2.49
- Resistance Level
- RIGL $41.25
- ABSI $3.40
- Average True Range (ATR)
- RIGL 2.50
- ABSI 0.19
- MACD
- RIGL 0.89
- ABSI -0.05
- Stochastic Oscillator
- RIGL 89.85
- ABSI 15.38
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.